Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02386098 · ClinicalTrials.gov registry record · Phase 2
Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults
A Phase 2 study, sponsored by ViiV Healthcare.
- Terminated
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
NCT02386098 is a Phase 2 study that was terminated before completion, run by ViiV Healthcare. The registered enrollment target is 86 participants.
The verdict
NCT02386098, a Phase 2 study, was terminated before completion, sponsored by ViiV Healthcare.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
Interventions
- DRUG BMS-955176
- DRUG Dolutegravir (DTG)
- DRUG Atazanavir (ATV)
- DRUG Ritonavir (RTV)
- DRUG Tenofovir (TDF)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2017-06-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02386098
The ClinicalTrials.gov registry entry for NCT02386098 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 86 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ViiV Healthcare, which has 182 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BMS-955176 is the first listed.
NCT02386098 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02386098 about?
NCT02386098 is a clinical study titled "Strategy-confirming Study of BMS-955176 to Treat HIV-1 Infected Treatment-experienced Adults". The purpose of this study is to evaluate whether the combination of BMS-955176 with atazanavir (ATV) \[with or without ritonavir (RTV)\] and dolutegravir (DTG) is efficacious, safe, and well-tolerated in HIV-1 infected treatment experienced adults.
What is the current status of trial NCT02386098?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2015-07-08. Estimated completion is 2017-06-07.
What interventions are being tested in trial NCT02386098?
The interventions under investigation include: BMS-955176 (DRUG), Dolutegravir (DTG) (DRUG), Atazanavir (ATV) (DRUG), Ritonavir (RTV) (DRUG), Tenofovir (TDF) (DRUG).
Who is sponsoring clinical trial NCT02386098?
This trial is sponsored by ViiV Healthcare, which has 182 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.